Literature DB >> 2857269

New tactics for type 2 diabetes: regimens based on intermediate-acting insulin taken at bedtime.

M C Riddle.   

Abstract

In type 2 diabetes mellitus, achieving normal fasting plasma glucose concentrations is probably more important than control of postprandial concentrations. It is suggested that, for some patients, treatment based on intermediate-acting insulin taken at bedtime will have more success than conventional regimens in lowering fasting, and thereby mean, plasma glucose concentrations, without causing hypoglycaemia.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2857269     DOI： 10.1016/s0140-6736(85)92029-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  6 in total

1.  Effects of a combination of bedtime intermediate-acting insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to respond to oral hypoglycaemic agents.

Authors:  M Krempf; T Godeau; S Ranganathan; P Blanchard; P Ritz; B Charbonnel
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents.

Authors:  S Stenman; P H Groop; C Saloranta; K J Tötterman; F Fyhrqvist; L Groop
Journal:  Diabetologia       Date:  1988-04       Impact factor: 10.122

Review 3.  When to use insulin in the maturity onset diabetic.

Authors:  R B Tattersall; A R Scott
Journal:  Postgrad Med J       Date:  1987-10       Impact factor: 2.401

4.  Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents.

Authors:  S Del Prato; S Vigili de Kreutzenberg; A Riccio; L Maifreni; E Duner; G Lisato; M Iavicoli; A Tiengo
Journal:  Diabetologia       Date:  1990-11       Impact factor: 10.122

Review 5.  The role of sulphonylureas in the management of type 2 diabetes mellitus.

Authors:  Marc Rendell
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C-peptide values before and after short-term intensive insulin therapy.

Authors:  Daisuke Fujiwara; Kenji Takahashi; Takahiro Suzuki; Masakazu Shii; Yukako Nakashima; Sato Takekawa; Atsushi Yoshida; Takashi Matsuoka
Journal:  J Diabetes Investig       Date:  2013-05-30       Impact factor: 4.232
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.